How much does a box of Asimini/Asnibu cost in 2025? Latest market prices and medical insurance status

Asciminib, also known as Asciminib, is a new oral targeted drug used to treat Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+CML). Its mechanism of action is unique and it is the world's first STAMP inhibitor, an inhibitor that "specifically targets the myelyl pocket of ABL", which is different from traditional ATP-competitive tyrosine kinase inhibitors. On May 14, 2025, Asnib was officially approved for marketing by the National Medical Products Administration in China, becoming a new option for the treatment of adult patients with Ph+CML in the chronic phase.

Currently, the main indication of Asiminib in China is newly diagnosed adult patients with Ph+CML-CP. This is an expanded application after the failure of multi-line treatment approved abroad. This drug can circumvent resistance problems caused by a variety of common mutations through a novel target mechanism, especially for patients who have failed or are intolerant to traditional TKIs (such as imatinib, nilotinib, dasatinib), providing an important clinical alternative. The uniqueness of its target also provides a basis for subsequent combination therapy or gradual replacement of older generation TKIs.

Regarding price, although Asnib is currently on the market in China, due to the short approval time, its official selling price and medical insurance reimbursement status have not yet been announced. It cannot be reimbursed through the medical insurance system for the time being, and patients need to pay for it themselves. Referring to the international market, the price of the original drug of Asnib is relatively expensive, especially in European and American countries. The original drug of 40mg specification and 60 tablets per bottle is usually priced at tens of thousands of RMB, which may fluctuate depending on exchange rate fluctuations.

In order to solve the problem of high treatment costs, some patients have also begun to pay attention to overseas generic drug channels. At present, the generic version of Asnib has been launched in Laos. Its active ingredients are basically the same as the original drug, and the dosage specifications and therapeutic uses are also similar. The price of generic drugs in Laos is generally around 2,000 yuan to 3,000 yuan per box, which is cost-effective and attractive to patients with limited financial conditions who require long-term maintenance treatment.

Reference materials:https://www.novartis.com/our-products/pipeline/asciminib